Imagion Biosystems Limited (Company) is committed to establishing a sound system of risk oversight and management and internal control to identify, assess, monitor and manage material risks related to the conduct of the Company’s activities.
Read the Imagion Biosystems Limited Risk Management Statement.
Positive independent review sets priority path to market for MagSense® Technology
February 5, 2023
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance